Drug Pricing Policy in the Inflation Reduction Act a Moderate But Manageable Negative to Biopharma

Retrieved on: 2022-08-02 15:49:06

Tags for this article:

Click the tags to see associated articles and topics

Drug Pricing Policy in the Inflation Reduction Act a Moderate But Manageable Negative to Biopharma. View article details on hiswai:

Excerpt

... Inflation Reduction Act of 2022 in our Big Biopharma valuation models. ... Part D cost-sharing to biopharma firms with more expensive drugs; ...

Article found on: www.morningstar.com